BAXTER INTL INC shareholders Q3 2020

BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,080 filers reported holding BAXTER INTL INC in Q3 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.

BAXTER INTL INC shareholders Q3 2020
NameSharesValueWeighting ↓
Nippon Life Global Investors Americas, Inc. 282,590$22,726,0001.50%
OLD POINT TRUST & FINANCIAL SERVICES N A 32,967$2,651,0001.46%
Svenska Handelsbanken AB (publ) 18,800$1,512,0001.44%
Destination Wealth Management 339,931$27,337,0001.38%
BLACKHILL CAPITAL INC 122,200$9,827,0001.33%
Rock Springs Capital Management LP 645,000$51,871,0001.32%
NuWave Investment Management, LLC 10,647$856,0001.32%
FULTON BREAKEFIELD BROENNIMAN LLC 140,456$11,295,0001.27%
Arjuna Capital 24,664$1,983,0001.23%
EQUITABLE TRUST CO 177,467$14,272,0001.22%
Addison Capital Co 21,316$1,714,0001.20%
Autus Asset Management, LLC 111,477$8,965,0001.19%
CSU Producer Resources, Inc. 4,400$354,0001.18%
Horrell Capital Management, Inc. 31,552$2,537,0001.18%
Wallington Asset Management, LLC 62,124$4,996,0001.16%
Palisade Asset Management, LLC 95,211$7,657,0001.15%
Rhenman & Partners Asset Management AB 155,000$12,465,0001.11%
BECK MACK & OLIVER LLC 371,391$29,867,0001.10%
HOWE & RUSLING INC 78,706$6,330,0001.09%
NORTH AMERICAN MANAGEMENT CORP 86,603$6,965,0001.08%
About BAXTER INTL INC

Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.

Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.

Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.

Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.

Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BAXTER INTL INC's shareholders in Q3 2020. To view BAXTER INTL INC's shareholder history, click here.